Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer vs. Merck and the Future of R&D

This article was originally published in RPM Report

Executive Summary

Two brand new CEOs take very different approaches to address the same problem: what to do about unrealistic expectations for growth in 2012. The different strategies chart different courses through a stressful period. We’ve seen this debate before, and it is hard to argue that either company prevailed last time around.

You may also be interested in...



FDA and the R&D Crisis: Time to Stop the Blame Game

Everyone knows R&D productivity has dipped to levels that threaten the private drug development model, and almost everyone says regulatory hurdles are part of the problem. That isn’t how FDA sees it. One thing is clear: blaming FDA won’t help anyone, so it may be time to pay more attention to FDA’s ideas for solutions rather than continue to point fingers.

Job One for Big Pharma: Repositioning in DC Post-Health Care Reform

How Wall Street’s reaction to the impact of health care reform may help the pharmaceutical industry make sure it pays off in the long run.

The Optics of Health Care Reform

There are plenty of reasons Wall Street doesn’t like health care reform. The biggest one, though, may be how hard it is to see over a cliff—the patent cliff that is resetting valuations across the Big Pharma sector.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel